Bristol-Myers Squibb Company
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 46.38B | 46.16B | 45.01B | 48.30B | 48.19B | -0.2% | |
| Cost of Revenue | (19.62B) | (19.67B) | (19.65B) | (20.87B) | (15.59B) | -25.3% | |
Gross Profit | 26.76B | 26.49B | 25.36B | 27.43B | 32.60B | 18.8% | |
| Operating Expenses | |||||||
| Research & Development | (9.53B) | (9.41B) | (9.21B) | (9.78B) | (9.61B) | -1.7% | |
| Selling, General & Administrative | (7.69B) | (7.81B) | (7.68B) | (7.87B) | (7.24B) | -7.9% | |
| General & Administrative | — | — | — | (6.37B) | (5.66B) | -11.1% | |
| Selling & Marketing | — | — | — | (1.50B) | (1.58B) | 5.6% | |
| Depreciation & Amortization | (10.69B) | (10.28B) | (9.76B) | (9.60B) | (3.86B) | -59.8% | |
Operating Income (EBIT) | 9.54B | 9.27B | 8.47B | 9.66B | 12.70B | 31.5% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | 300.00M | — | |
| Interest Expense | (1.33B) | (1.23B) | (1.17B) | (1.95B) | (1.51B) | -22.4% | |
| Other Income/Expenses (Net) | -1.44B | -1.56B | -32.00M | -18.04B | -3.37B | -81.3% | |
Income Before Tax | 8.10B | 7.71B | 8.44B | -8.38B | 9.33B | -211.3% | |
| Income Tax Expense | (1.08B) | (1.37B) | (400.00M) | (554.00M) | (2.27B) | 310.1% | |
Net Income | 6.99B | 6.33B | 8.03B | -8.95B | 7.05B | -178.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $3 | $3 | $4 | $-4 | $3 | -178.5% | |
| Weighted Avg Shares Outstanding | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B | 0.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B | 0.7% | |
EBITDA | 20.12B | 19.22B | 19.37B | 3.17B | 14.54B | 359.1% |
Explore BMY
BMY in the Healthcare
Large Cap